<SEC-DOCUMENT>0001104659-24-113576.txt : 20241101
<SEC-HEADER>0001104659-24-113576.hdr.sgml : 20241101
<ACCEPTANCE-DATETIME>20241101191453
ACCESSION NUMBER:		0001104659-24-113576
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20241030
FILED AS OF DATE:		20241101
DATE AS OF CHANGE:		20241101

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Hahn Mark W
		CENTRAL INDEX KEY:			0001408502
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		241420419

	MAIL ADDRESS:	
		STREET 1:		6340 QUADRANGLE DRIVE
		STREET 2:		SUITE 100
		CITY:			CHAPEL HILL
		STATE:			NC
		ZIP:			27517

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2427350-2_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-10-30</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001657312</issuerCik>
        <issuerName>Verona Pharma plc</issuerName>
        <issuerTradingSymbol>VRNA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001408502</rptOwnerCik>
            <rptOwnerName>Hahn Mark W</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>3 MORE LONDON</rptOwnerStreet1>
            <rptOwnerStreet2>RIVERSIDE</rptOwnerStreet2>
            <rptOwnerCity>LONDON</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>SE1 2RE</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2024-10-30</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>800000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>14469360</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2024-11-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F3"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>200000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>14669360</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2024-11-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F4"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>245952</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.2412</value>
                    <footnoteId id="F5"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>14423408</value>
                    <footnoteId id="F6"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Reported securities are represented by American Depositary Shares (&quot;ADSs&quot;), each of which represents eight (8) Ordinary Shares of the Issuer.</footnote>
        <footnote id="F2">Represents an award of Restricted Share Units (&quot;RSUs&quot;), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 1/4th of the RSUs vesting on November 1, 2025 and the balance vesting in 12 equal quarterly installments thereafter.</footnote>
        <footnote id="F3">Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine.</footnote>
        <footnote id="F4">Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units and the vesting of the Performance Restricted Share Units described in footnote 3 above.</footnote>
        <footnote id="F5">The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2024 divided by eight (8).</footnote>
        <footnote id="F6">Consists of (i) 3,000,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 375,000 ADSs); and (ii) 11,423,408 Ordinary Shares underlying 1,427,926 ADSs.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Andrew Fisher, Attorney-in-Fact for Mark Hahn</signatureName>
        <signatureDate>2024-11-01</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
